Quantcast
Last updated on April 16, 2014 at 10:37 EDT

Latest Cell Therapeutics Inc. Stories

2012-10-26 03:20:48

SEATTLE, Oct. 26, 2012 /PRNewswire/ -- On Tuesday, October 30, 2012, at 8:30 a.m. Eastern/1:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (NASDAQ and MTA: CTIC) management team will host a conference call to discuss the Company's 2012 third quarter achievements and financial results. Conference Call Numbers Tuesday, October 30(th) 8:30 a.m. Eastern/1:30 p.m. Central European/5:30 a.m. Pacific Time 1-877-941-2333 (US Participants)...

2012-10-15 03:22:11

SEATTLE, Oct. 15, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that CT-1578's (previously known as SB-1578) unique kinase spectrum that selectively inhibits JAK2 over JAK1 or JAK3, coupled with its inhibition of FLT-3 and c-Fms, produced potency in not only preventing the development of rheumatoid arthritis ("RA"), but also in its treatment and reversal of bone and joint destruction after the onset of RA in preclinical models according to results...

2012-10-08 07:26:51

VANCOUVER, British Columbia, Oct. 8, 2012 /PRNewswire/ -- Insiderslab.com has issued insider trading reports and Equity Research for the following companies: Citigroup (NYSE:C), Hewlett-Packard (NYSE:HPQ), Avon Products (NYSE:AVP), Cell Therapeutics (NASDAQ:CTIC), FLEETMATICS (NYSE:FLTX), and Energy Transfer Partners (NYSE:ETP). (Logo: http://photos.prnewswire.com/prnh/20100419/HKM001LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full...

2012-10-04 22:20:31

SEATTLE, Oct. 5, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced the pricing of an underwritten public offering of 60,000 shares of its Series 17 Preferred Stock, offered at a price to the public of $1,000 per share of Series 17 Preferred Stock (the "Offering"). Each share of Series 17 Preferred Stock is convertible at the option of the holder, at any time, into approximately 714 shares of common stock at a conversion price of $1.40 per share of...

2012-10-04 02:25:55

SEATTLE, Oct. 4, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it intends to offer and sell, subject to market and other conditions, 40,000 shares of its Series 17 Preferred Stock in an underwritten public offering(the "Offering"). Each share of Series 17 Preferred Stock will have a stated value of $1,000 per share and will be convertible at the option of the holder, at any time after issuance, into shares of common stock prior to the...

2012-10-01 22:20:55

SEATTLE, Oct. 2, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced that OPAXIO (paclitaxel poliglumex) has been granted orphan-drug designation by the U.S Food and Drug Administration ("FDA") for the treatment of glioblastoma multiforme ("GBM"), a malignant brain cancer. Orphan designation was granted based on preliminary activity seen from phase 2 results of OPAXIO when added to standard therapy (temozolamide ("TMZ") plus radiation). In this study,...

2012-09-23 22:22:03

SEATTLE, Sept. 24, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the phase 1 study data of its highly selective oral JAK2 inhibitor pacritinib, or SB1518, showed encouraging anti-tumor activity and good tolerability in 34 patients with relapsed/refractory lymphoma. The results were published online in the Journal of Clinical Oncology in September, 2012. Thirty-four patients received daily oral doses of pacritinib ranging from 100mg to...

2012-09-18 22:21:08

SEATTLE, Sept. 19, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced that it has received a letter from The NASDAQ Stock Market LLC (the "NASDAQ"), indicating that CTI has regained compliance with the minimum bid price rule (NASDAQ Listing Rule 5550(a)(2)) . About Cell Therapeutics, Inc. Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more...

2012-09-12 02:37:50

VANCOUVER, British Columbia, Sept. 12, 2012 /PRNewswire/ -- Insiderslab.com has issued insider trading reports and Equity Research for the following companies: Sprint Nextel (NYSE:S), Coach (NYSE:COH), Alpha Natural Resources (NYSE:ANR), Lowe's (NYSE:LOW), Nuance (NASDAQ:NUAN), and Cell Therapeutics (NASDAQ:CTIC). (Logo: http://photos.prnewswire.com/prnh/20100419/HKM001LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link to your browser.) Report...

2012-09-10 22:23:08

SEATTLE, Sept. 11, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC), a company focused on translating science into novel cancer therapies, today announced the initiation of the commercial launch of Pixuvri® in the European Union ("E.U.") with entry into Sweden, Denmark and Finland in September, to be followed by Austria and Norway in early October 2012 and Germany, United Kingdom and the Netherlands in November 2012. CTI plans to expand availability to France,...